1,3,4,5-Tetrahydro-1,3-dimethyl-1-benzazocin-2(1H)-one | 133901-57-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 1,3,4,5-Tetrahydro-1,3-dimethyl-1-benzazocin-2(1H)-one
• 英文别名: 1,3-Dimethyl-3,4,5,6-tetrahydro-1-benzazocin-2-one
• CAS: 133901-57-2
• 化学式: C₁₃H₁₇NO
• 分子量: 203.284
• InChiKey: BFMPUPODDAVQLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-烯丙基-N-甲基苯胺 在 吡啶 、 4-二甲氨基吡啶 、 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 甲苯 为溶剂， 反应 3.5h， 生成 1,3,4,5-Tetrahydro-1,3-dimethyl-1-benzazocin-2(1H)-one
  参考文献：
  名称：

  Sato, Tatsunori; Ishida, Satoshi; Ishibashi, Hiroyuki, Journal of the Chemical Society. Perkin transactions I, 1991, # 2, p. 353 - 359

  摘要：

  DOI：

文献信息

• Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
  申请人：Gilead Sciences, Inc.

  公开号：US11084832B2

  公开（公告）日：2021-08-10

  Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明公开了用于治疗或预防人类免疫缺陷病毒（HIV）感染的化合物。这些化合物具有下式(I)： 其中 R1、R2、L、W1、W2、X、Y 和 Z 如本文所定义。此外，还公开了与制备和使用此类化合物相关的方法，以及包含此类化合物的药物组合物。
• SATO, TATSUNORI;ISHIDA, SATOSHI;ISHIBASHI, HIROYUKI;IKEDA, MASAZUMI, J. CHEM. SOC. PERKIN TRANS. PT 1,(1991) N, C. 353-359
  作者：SATO, TATSUNORI、ISHIDA, SATOSHI、ISHIBASHI, HIROYUKI、IKEDA, MASAZUMI

  DOI：——

  日期：——
• BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
  申请人：Gilead Sciences, Inc.

  公开号：US20200317689A1

  公开（公告）日：2020-10-08

  Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , L, W 1 , W 2 , X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.